NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk, has announced its participation in multiple investor conferences in March 2025.

The company will attend the TD Cowen 45th Annual Healthcare Conference in Boston on March 4-5, where CEO Michael Davidson and CFO Ian Somaiya will present a corporate overview on March 4 at 1:50 p.m. ET.

Additionally, NAMS will participate in the Leerink Partners Global Healthcare Conference in Miami on March 10, with Dr. Davidson presenting at 8:00 a.m. ET, and the Jefferies Biotech on the Beach Summit in Miami on March 12, where management will be available for one-on-one meetings.

Live webcasts of the presentations will be accessible through the investor relations section of the company's website, with archived replays available afterward.

Positive

• NewAmsterdam Pharma is actively engaging with investors through participation in multiple high-profile healthcare conferences
• The company's focus on non-statin medicines addresses an important market gap for patients with cardiovascular disease risk
• NAMS is providing transparent investor access through live webcasts of their presentations
• Senior leadership including the CEO and CFO are directly participating in these investor events

Negative

• The press release doesn't provide details about the company's current clinical trial progress
• No financial updates or business developments were included in the announcement
• The company is still in late-stage clinical development without marketed products mentioned

News Market Reaction

+2.00%

1 alert

+2.00% News Effect

On the day this news was published, NAMS gained 2.00%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

• TD Cowen 45^th Annual Healthcare Conference in Boston, MA on Tuesday, March 4 and Wednesday, March 5, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 1:50 p.m. ET on Tuesday, March 4.
• Leerink Partners Global Healthcare Conference 2025 in Miami, FL on Monday, March 10, 2025. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 8:00 a.m. ET.
• Jefferies Biotech on the Beach Summit in Miami, FL on Wednesday, March 12, 2025. Company management will be available for 1x1 meetings throughout the day.
  

Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
jleady@spectrumscience.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

What investor conferences will NewAmsterdam Pharma (NAMS) attend in March 2025?

NewAmsterdam Pharma will participate in three investor conferences in March 2025: TD Cowen 45th Annual Healthcare Conference in Boston (March 4-5), Leerink Partners Global Healthcare Conference in Miami (March 10), and Jefferies Biotech on the Beach Summit in Miami (March 12).

When will NAMS CEO Michael Davidson present at the TD Cowen Healthcare Conference?

Michael Davidson, CEO of NewAmsterdam Pharma, will present a corporate overview at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 1:50 p.m. ET.

How can investors access NewAmsterdam Pharma's (NAMS) conference presentations?

Investors can access live webcasts of NewAmsterdam Pharma's presentations through the investor relations section of the company's website at ir.newamsterdampharma.com. Archived replays will also be available on the website following the live webcasts.

What type of medicines is NewAmsterdam Pharma (NAMS) developing?

NewAmsterdam Pharma is developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated.

Which executives from NAMS will attend the March 2025 investor conferences?

Michael Davidson, M.D., Chief Executive Officer, will attend all three conferences. Ian Somaiya, Chief Financial Officer, is confirmed to join the TD Cowen conference presentation. The company also noted that management will be available for one-on-one meetings at the Jefferies summit.